Merck immunotherapy fails to improve survival in head and neck cancer

(Reuters) - Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial.